AU2006279395A1 - Ocular gene therapy using avalanche-mediated transfection - Google Patents
Ocular gene therapy using avalanche-mediated transfection Download PDFInfo
- Publication number
- AU2006279395A1 AU2006279395A1 AU2006279395A AU2006279395A AU2006279395A1 AU 2006279395 A1 AU2006279395 A1 AU 2006279395A1 AU 2006279395 A AU2006279395 A AU 2006279395A AU 2006279395 A AU2006279395 A AU 2006279395A AU 2006279395 A1 AU2006279395 A1 AU 2006279395A1
- Authority
- AU
- Australia
- Prior art keywords
- set forth
- cells
- tissue
- nucleic acid
- gene
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 238000001890 transfection Methods 0.000 title claims description 29
- 230000001404 mediated effect Effects 0.000 title claims description 13
- 238000001415 gene therapy Methods 0.000 title description 11
- 210000004027 cell Anatomy 0.000 claims description 103
- 210000001519 tissue Anatomy 0.000 claims description 94
- 108090000623 proteins and genes Proteins 0.000 claims description 85
- 238000000034 method Methods 0.000 claims description 53
- 150000007523 nucleic acids Chemical class 0.000 claims description 48
- 102000004169 proteins and genes Human genes 0.000 claims description 38
- 102000039446 nucleic acids Human genes 0.000 claims description 33
- 108020004707 nucleic acids Proteins 0.000 claims description 33
- 230000001225 therapeutic effect Effects 0.000 claims description 29
- 239000013612 plasmid Substances 0.000 claims description 27
- 239000003550 marker Substances 0.000 claims description 25
- 102100034343 Integrase Human genes 0.000 claims description 11
- 108010061833 Integrases Proteins 0.000 claims description 11
- 206010025421 Macule Diseases 0.000 claims description 9
- 210000002950 fibroblast Anatomy 0.000 claims description 7
- 108091006047 fluorescent proteins Proteins 0.000 claims description 7
- 102000034287 fluorescent proteins Human genes 0.000 claims description 7
- 208000022873 Ocular disease Diseases 0.000 claims description 6
- 210000004127 vitreous body Anatomy 0.000 claims description 6
- 108091027967 Small hairpin RNA Proteins 0.000 claims description 5
- 206010064930 age-related macular degeneration Diseases 0.000 claims description 5
- 201000010099 disease Diseases 0.000 claims description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 5
- 208000002780 macular degeneration Diseases 0.000 claims description 5
- 210000003583 retinal pigment epithelium Anatomy 0.000 claims description 5
- 210000003786 sclera Anatomy 0.000 claims description 5
- 239000004055 small Interfering RNA Substances 0.000 claims description 5
- 108091034117 Oligonucleotide Proteins 0.000 claims description 4
- 108091030071 RNAI Proteins 0.000 claims description 4
- 210000002919 epithelial cell Anatomy 0.000 claims description 4
- 230000009368 gene silencing by RNA Effects 0.000 claims description 4
- 230000008439 repair process Effects 0.000 claims description 4
- 208000005590 Choroidal Neovascularization Diseases 0.000 claims description 3
- 206010060823 Choroidal neovascularisation Diseases 0.000 claims description 3
- 230000000735 allogeneic effect Effects 0.000 claims description 3
- 230000001772 anti-angiogenic effect Effects 0.000 claims description 3
- 210000003161 choroid Anatomy 0.000 claims description 3
- 230000006801 homologous recombination Effects 0.000 claims description 3
- 238000002744 homologous recombination Methods 0.000 claims description 3
- 230000000508 neurotrophic effect Effects 0.000 claims description 3
- 102000016550 Complement Factor H Human genes 0.000 claims description 2
- 108010053085 Complement Factor H Proteins 0.000 claims description 2
- 206010012689 Diabetic retinopathy Diseases 0.000 claims description 2
- 208000010412 Glaucoma Diseases 0.000 claims description 2
- 208000032430 Retinal dystrophy Diseases 0.000 claims description 2
- 239000002775 capsule Substances 0.000 claims description 2
- 230000000694 effects Effects 0.000 claims description 2
- 230000001939 inductive effect Effects 0.000 claims description 2
- 230000037361 pathway Effects 0.000 claims description 2
- 210000001423 scleral cell Anatomy 0.000 claims description 2
- 241000124008 Mammalia Species 0.000 claims 1
- 201000007737 Retinal degeneration Diseases 0.000 claims 1
- 238000012258 culturing Methods 0.000 claims 1
- 239000012530 fluid Substances 0.000 claims 1
- 230000004258 retinal degeneration Effects 0.000 claims 1
- 230000005684 electric field Effects 0.000 description 27
- 230000014509 gene expression Effects 0.000 description 23
- 239000013598 vector Substances 0.000 description 21
- 108020004414 DNA Proteins 0.000 description 20
- 238000005215 recombination Methods 0.000 description 17
- 102100035846 Pigment epithelium-derived factor Human genes 0.000 description 16
- 108090000102 pigment epithelium-derived factor Proteins 0.000 description 16
- 230000006798 recombination Effects 0.000 description 16
- 108020004684 Internal Ribosome Entry Sites Proteins 0.000 description 15
- 239000000523 sample Substances 0.000 description 15
- 241000701022 Cytomegalovirus Species 0.000 description 12
- 108010048367 enhanced green fluorescent protein Proteins 0.000 description 12
- 238000002054 transplantation Methods 0.000 description 12
- 108091028043 Nucleic acid sequence Proteins 0.000 description 10
- 239000002609 medium Substances 0.000 description 10
- 108091033319 polynucleotide Proteins 0.000 description 10
- 102000040430 polynucleotide Human genes 0.000 description 10
- 239000002157 polynucleotide Substances 0.000 description 10
- 108060001084 Luciferase Proteins 0.000 description 9
- 239000002773 nucleotide Substances 0.000 description 9
- 125000003729 nucleotide group Chemical group 0.000 description 9
- 239000000758 substrate Substances 0.000 description 9
- 229920001184 polypeptide Polymers 0.000 description 8
- 108090000765 processed proteins & peptides Proteins 0.000 description 8
- 102000004196 processed proteins & peptides Human genes 0.000 description 8
- 238000013519 translation Methods 0.000 description 7
- 108700039691 Genetic Promoter Regions Proteins 0.000 description 5
- 239000005089 Luciferase Substances 0.000 description 5
- 210000000795 conjunctiva Anatomy 0.000 description 5
- 238000004520 electroporation Methods 0.000 description 5
- 230000010354 integration Effects 0.000 description 5
- 230000028327 secretion Effects 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- 108091026890 Coding region Proteins 0.000 description 4
- 230000001464 adherent effect Effects 0.000 description 4
- 238000013459 approach Methods 0.000 description 4
- 238000001727 in vivo Methods 0.000 description 4
- 238000009834 vaporization Methods 0.000 description 4
- 230000008016 vaporization Effects 0.000 description 4
- 201000004569 Blindness Diseases 0.000 description 3
- 102000008579 Transposases Human genes 0.000 description 3
- 108010020764 Transposases Proteins 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 230000002051 biphasic effect Effects 0.000 description 3
- 230000001413 cellular effect Effects 0.000 description 3
- 238000013461 design Methods 0.000 description 3
- 210000003527 eukaryotic cell Anatomy 0.000 description 3
- 239000012634 fragment Substances 0.000 description 3
- 210000005260 human cell Anatomy 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 230000007774 longterm Effects 0.000 description 3
- 239000011159 matrix material Substances 0.000 description 3
- 230000004083 survival effect Effects 0.000 description 3
- 238000013518 transcription Methods 0.000 description 3
- 230000035897 transcription Effects 0.000 description 3
- 230000003612 virological effect Effects 0.000 description 3
- 230000004393 visual impairment Effects 0.000 description 3
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 2
- 108091023037 Aptamer Proteins 0.000 description 2
- 102000008137 Bone Morphogenetic Protein 4 Human genes 0.000 description 2
- 108010049955 Bone Morphogenetic Protein 4 Proteins 0.000 description 2
- 102000004219 Brain-derived neurotrophic factor Human genes 0.000 description 2
- 108090000715 Brain-derived neurotrophic factor Proteins 0.000 description 2
- 108010005939 Ciliary Neurotrophic Factor Proteins 0.000 description 2
- 102100031614 Ciliary neurotrophic factor Human genes 0.000 description 2
- IGXWBGJHJZYPQS-SSDOTTSWSA-N D-Luciferin Chemical compound OC(=O)[C@H]1CSC(C=2SC3=CC=C(O)C=C3N=2)=N1 IGXWBGJHJZYPQS-SSDOTTSWSA-N 0.000 description 2
- CYCGRDQQIOGCKX-UHFFFAOYSA-N Dehydro-luciferin Natural products OC(=O)C1=CSC(C=2SC3=CC(O)=CC=C3N=2)=N1 CYCGRDQQIOGCKX-UHFFFAOYSA-N 0.000 description 2
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 2
- 102000018233 Fibroblast Growth Factor Human genes 0.000 description 2
- 108050007372 Fibroblast Growth Factor Proteins 0.000 description 2
- BJGNCJDXODQBOB-UHFFFAOYSA-N Fivefly Luciferin Natural products OC(=O)C1CSC(C=2SC3=CC(O)=CC=C3N=2)=N1 BJGNCJDXODQBOB-UHFFFAOYSA-N 0.000 description 2
- DDWFXDSYGUXRAY-UHFFFAOYSA-N Luciferin Natural products CCc1c(C)c(CC2NC(=O)C(=C2C=C)C)[nH]c1Cc3[nH]c4C(=C5/NC(CC(=O)O)C(C)C5CC(=O)O)CC(=O)c4c3C DDWFXDSYGUXRAY-UHFFFAOYSA-N 0.000 description 2
- 240000007019 Oxalis corniculata Species 0.000 description 2
- 102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 description 2
- 108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 description 2
- 241000709664 Picornaviridae Species 0.000 description 2
- 102000018120 Recombinases Human genes 0.000 description 2
- 108010091086 Recombinases Proteins 0.000 description 2
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 description 2
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 2
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 2
- 230000003115 biocidal effect Effects 0.000 description 2
- 238000005415 bioluminescence Methods 0.000 description 2
- 230000029918 bioluminescence Effects 0.000 description 2
- 229940077737 brain-derived neurotrophic factor Drugs 0.000 description 2
- 239000002299 complementary DNA Substances 0.000 description 2
- 210000004087 cornea Anatomy 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 238000005538 encapsulation Methods 0.000 description 2
- 210000000981 epithelium Anatomy 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 229940126864 fibroblast growth factor Drugs 0.000 description 2
- 238000000799 fluorescence microscopy Methods 0.000 description 2
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 2
- 230000030279 gene silencing Effects 0.000 description 2
- 238000012226 gene silencing method Methods 0.000 description 2
- 230000028993 immune response Effects 0.000 description 2
- 238000002513 implantation Methods 0.000 description 2
- 210000004962 mammalian cell Anatomy 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 108020004999 messenger RNA Proteins 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012544 monitoring process Methods 0.000 description 2
- 210000000663 muscle cell Anatomy 0.000 description 2
- 210000005036 nerve Anatomy 0.000 description 2
- 230000008823 permeabilization Effects 0.000 description 2
- 125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 description 2
- 239000000049 pigment Substances 0.000 description 2
- 239000011148 porous material Substances 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 108091008146 restriction endonucleases Proteins 0.000 description 2
- 210000001525 retina Anatomy 0.000 description 2
- 108091008601 sVEGFR Proteins 0.000 description 2
- 230000035939 shock Effects 0.000 description 2
- 230000001360 synchronised effect Effects 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 241001430294 unidentified retrovirus Species 0.000 description 2
- BJHCYTJNPVGSBZ-YXSASFKJSA-N 1-[4-[6-amino-5-[(Z)-methoxyiminomethyl]pyrimidin-4-yl]oxy-2-chlorophenyl]-3-ethylurea Chemical compound CCNC(=O)Nc1ccc(Oc2ncnc(N)c2\C=N/OC)cc1Cl BJHCYTJNPVGSBZ-YXSASFKJSA-N 0.000 description 1
- CPKVUHPKYQGHMW-UHFFFAOYSA-N 1-ethenylpyrrolidin-2-one;molecular iodine Chemical compound II.C=CN1CCCC1=O CPKVUHPKYQGHMW-UHFFFAOYSA-N 0.000 description 1
- 101150096316 5 gene Proteins 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 102400000068 Angiostatin Human genes 0.000 description 1
- 108010079709 Angiostatins Proteins 0.000 description 1
- 208000002177 Cataract Diseases 0.000 description 1
- 102000004594 DNA Polymerase I Human genes 0.000 description 1
- 108010017826 DNA Polymerase I Proteins 0.000 description 1
- 206010061818 Disease progression Diseases 0.000 description 1
- 206010059866 Drug resistance Diseases 0.000 description 1
- 208000003556 Dry Eye Syndromes Diseases 0.000 description 1
- 206010013774 Dry eye Diseases 0.000 description 1
- 241000710188 Encephalomyocarditis virus Species 0.000 description 1
- 102400001047 Endostatin Human genes 0.000 description 1
- 108010079505 Endostatins Proteins 0.000 description 1
- 241000991587 Enterovirus C Species 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 108700028146 Genetic Enhancer Elements Proteins 0.000 description 1
- 108010043121 Green Fluorescent Proteins Proteins 0.000 description 1
- 102000004144 Green Fluorescent Proteins Human genes 0.000 description 1
- 101001023784 Heteractis crispa GFP-like non-fluorescent chromoprotein Proteins 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 206010062016 Immunosuppression Diseases 0.000 description 1
- 108091026898 Leader sequence (mRNA) Proteins 0.000 description 1
- 102000006830 Luminescent Proteins Human genes 0.000 description 1
- 108010047357 Luminescent Proteins Proteins 0.000 description 1
- 102000005741 Metalloproteases Human genes 0.000 description 1
- 108010006035 Metalloproteases Proteins 0.000 description 1
- 108700026244 Open Reading Frames Proteins 0.000 description 1
- 238000012408 PCR amplification Methods 0.000 description 1
- 102000045595 Phosphoprotein Phosphatases Human genes 0.000 description 1
- 108700019535 Phosphoprotein Phosphatases Proteins 0.000 description 1
- 241001144416 Picornavirales Species 0.000 description 1
- 108010076504 Protein Sorting Signals Proteins 0.000 description 1
- 208000017442 Retinal disease Diseases 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- 241000701955 Streptomyces virus phiC31 Species 0.000 description 1
- 108700019146 Transgenes Proteins 0.000 description 1
- 108091023045 Untranslated Region Proteins 0.000 description 1
- 208000027076 Uveal disease Diseases 0.000 description 1
- 108010053096 Vascular Endothelial Growth Factor Receptor-1 Proteins 0.000 description 1
- 108010053099 Vascular Endothelial Growth Factor Receptor-2 Proteins 0.000 description 1
- 102100033178 Vascular endothelial growth factor receptor 1 Human genes 0.000 description 1
- 102100033177 Vascular endothelial growth factor receptor 2 Human genes 0.000 description 1
- 241000021375 Xenogenes Species 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 238000004873 anchoring Methods 0.000 description 1
- 230000000416 anti-micotic effect Effects 0.000 description 1
- 210000004507 artificial chromosome Anatomy 0.000 description 1
- FZCSTZYAHCUGEM-UHFFFAOYSA-N aspergillomarasmine B Natural products OC(=O)CNC(C(O)=O)CNC(C(O)=O)CC(O)=O FZCSTZYAHCUGEM-UHFFFAOYSA-N 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 229940064804 betadine Drugs 0.000 description 1
- 238000001574 biopsy Methods 0.000 description 1
- 210000001775 bruch membrane Anatomy 0.000 description 1
- 244000309466 calf Species 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 230000012292 cell migration Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 210000000991 chicken egg Anatomy 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 239000013068 control sample Substances 0.000 description 1
- 210000004748 cultured cell Anatomy 0.000 description 1
- 108010082025 cyan fluorescent protein Proteins 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 230000003292 diminished effect Effects 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- 230000005750 disease progression Effects 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 210000005081 epithelial layer Anatomy 0.000 description 1
- 230000003628 erosive effect Effects 0.000 description 1
- 238000000684 flow cytometry Methods 0.000 description 1
- 108010021843 fluorescent protein 583 Proteins 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- 239000005090 green fluorescent protein Substances 0.000 description 1
- 230000005847 immunogenicity Effects 0.000 description 1
- 230000001506 immunosuppresive effect Effects 0.000 description 1
- 239000007943 implant Substances 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 239000003999 initiator Substances 0.000 description 1
- 238000009413 insulation Methods 0.000 description 1
- 239000012212 insulator Substances 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 230000002147 killing effect Effects 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 238000002324 minimally invasive surgery Methods 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 238000011587 new zealand white rabbit Methods 0.000 description 1
- 210000001328 optic nerve Anatomy 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 239000002953 phosphate buffered saline Substances 0.000 description 1
- 239000004417 polycarbonate Substances 0.000 description 1
- 229920000515 polycarbonate Polymers 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 230000001902 propagating effect Effects 0.000 description 1
- ZMRUPTIKESYGQW-UHFFFAOYSA-N propranolol hydrochloride Chemical compound [H+].[Cl-].C1=CC=C2C(OCC(O)CNC(C)C)=CC=CC2=C1 ZMRUPTIKESYGQW-UHFFFAOYSA-N 0.000 description 1
- 210000001747 pupil Anatomy 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000022532 regulation of transcription, DNA-dependent Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000002207 retinal effect Effects 0.000 description 1
- 210000003705 ribosome Anatomy 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 239000003860 topical agent Substances 0.000 description 1
- 238000002691 topical anesthesia Methods 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- 241000701161 unidentified adenovirus Species 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
- 239000013603 viral vector Substances 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- 108091005957 yellow fluorescent proteins Proteins 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/81—Protease inhibitors
- C07K14/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
- C07K14/811—Serine protease (E.C. 3.4.21) inhibitors
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Ophthalmology & Optometry (AREA)
- Medicinal Chemistry (AREA)
- General Engineering & Computer Science (AREA)
- Zoology (AREA)
- Veterinary Medicine (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Biophysics (AREA)
- Public Health (AREA)
- Biochemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Wood Science & Technology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Microbiology (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Description
WO 2007/022403 PCT/US2006/032249 OCULAR GENE THERAPY USING AVALANCHE-MEDIATED TRANSFECTION FIELD OF THE INVENTION 5 The present invention relates generally to medicine. More particularly, the present invention relates to a method of treating ocular diseases with gene therapy using avalanche-mediated transfection to genetically modify cells or tissue. BACKGROUND 10 There are many ocular diseases that affect vision. Diseases of the conjunctiva and cornea, cataracts, uveal diseases, retinal diseases, loss of central acuity and visual field abnormalities and diseases of Bruch's membrane are a few examples. Age-related macular degeneration is a leading cause of vision loss in the aged population. In the less common but more severe "wet" form of age-related macular degeneration, choroidal neovascularization leads to progressive 15 disease and vision loss. Current therapeutics for treatment of many ocular conditions require the need for frequent intravitreal administration. Therapies involving delivery of proteins or aptamers are examples of such approaches, with the drawback that proteins and aptamers have short half-lives and require 20 intravitreal administration every 4-6 weeks for life for maximal efficacy. Gene therapy approaches are potentially more long-term, with the possibility of lasting many months or years. Gene therapy can be in vivo, involving delivery of therapeutic genes directly to the tissue of interest, or can be ex vivo, where tissue selected for use is treated outside the body prior to implantation. The art has long sought gene therapy treatment methods that are safe for the 25 patient and therapeutically viable. 1 WO 2007/022403 PCT/US2006/032249 One of the important factors in the efficacy and safety of gene therapy is the method used to introduce DNA into a cell. Viral vectors, such as retroviruses and adenoviruses, enable high expression of the introduced DNA but have safety concerns. Non-viral methods, such as liposomes, have low host immunogenicity but tend to suffer from inefficient DNA delivery to 5 cells. Accordingly, there is a need in the art for new methods of introducing DNA into cells and tissues for the purpose of gene therapy. 2 WO 2007/022403 PCT/US2006/032249 SUMMARY OF THE INVENTION The present invention provides a method of treating an ocular disease in a subject. In a first step, a nucleic acid is introduced into cells or a tissue. The nucleic acid is introduced by electron avalanche-mediated transfection. With this technique, a high electric field induces a vapor 5 bubble and plasma discharge between an electrode and the surrounding medium. The formation of a vapor bubble generates mechanical stress. Plasma discharge through the ionized vapor in the bubble enables connectivity between the electrode and the surrounding medium, so that the mechanical stress and electric field are applied simultaneously, which results in permeabilization of the cells or tissue. This penneabilization in turn allows the nucleic acid to enter the cell or 10 tissue. Cells or tissue containing the nucleic acid are then transplanted into an ocular region of the subject. Cells and tissue according to the present invention are preferably autologous (i.e. from the subject), or allogeneic (i.e. from an individual of the same species). In the case of cells, the cells 15 may be primary cells or cell lines. Preferred primary cells are conjunctival fibroblasts,_scleral cells, or epithelial cells. Preferred cell lines are fibroblast cell lines or muscle cell lines. Preferred tissues are conjunctival tissue and scleral tissue. The cells or tissue may be cultured prior to transplantation. Alternatively, or in addition, the cells or tissue may be placed in a cage, such as a polymeric cage, or a scaffold or matrix to support the growth of the cells. 20 In a preferred embodiment, the nucleic acid is DNA. The DNA may encode, for example, a therapeutic protein or an RNAi cassette, such as a short-hairpin RNA (shRNA). Alternatively, the DNA may be used for modifying an endogenous gene. For example, the DNA may be an oligonucleotide used for gene repair, or may be used for homologous recombination with an 25 endogenous gene, for the purpose of modifying the gene. Modifications include, for example, modifying expression levels of the gene and/or replacing a mutant gene with a wild-type copy of 3 WO 2007/022403 PCT/US2006/032249 the gene. In a particularly preferred embodiment, the nucleic acid is part of a plasmid. The plasmid may, in addition to a therapeutic gene, contain a marker gene. In order to obtain genomic integration, the plasmid may contain integration elements, such as a phiC31 attB site or inverted repeats recognized by transposases such as Sleeping Beauty. In this case, a source of 5 phiC31 integrase or a transposase would also be provided. Genetically-modified cells or tissue may be transplanted into any ocular region of the subject. Preferred regions are the choroid, vitreous humor, retinal pigment epithelium, near the macula, and behind the sclera. In the case of a macular region, the ocular region may be epiretinal to the 10 macula, subretinal to the macula, or intra-retinal to the macula. In the case of the vitreous humor, the ocular region is preferably a region of the vitreous humor near the pars plana. Any ocular disease may be treated according to the present invention. Examples include, but are not limited to, age-related macular degeneration, choroidal neovascularization, retinal 15 degeneration, glaucoma, diabetic retinopathy, and retinal dystrophies. Similarly, any subject may be treated according to the present invention. Preferred subjects are humans and non human mammals. BRIEF DESCRIPTION OF THE FIGURES 20 The present invention together with its objectives and advantages will be understood by reading the following description in conjunction with the drawings, in which: FIG. 1 shows the avalanche method according to the present invention. FIG. 2 shows the use of the avalanche method according to the present invention with wire electrodes. 25 FIGS. 3-6 show examples of electrode geometries suitable for practicing the avalanche method according to the present invention. 4 WO 2007/022403 PCT/US2006/032249 FIG. 7 shows an example of a plasmid construct suitable for gene therapy of an ocular disease according to the present invention. The plasmid contains a nucleotide sequence encoding for pigment epithelium-derived factor (PEDF) and a nucleotide sequence encoding for enhanced green fluorescent protein (eGFP) 5 under control of a cytomegalovirus (CMV) promoter, the two sequences linked by an internal ribosome entry site (IRES) coding sequence. FIG. 8 shows ocular regions suitable for transplantation according to the present invention. FIG. 9-10 show examples of electron avalanche-mediated transfection according to the 10 present invention. DETAILED DESCRIPTION OF THE INVENTION Avalanche method The present invention provides an ex vivo gene therapy method based on a novel method of 15 introducing DNA into cells called the avalanche method. When sufficiently high voltage is applied to an electrode, a mechanical stress wave synchronized with a pulse of electric current can be produced and applied to cells or tissue, as shown in FIG. 1. FIG. 1A-C shows three stages that occur when a high voltage is applied to an electrode 110 covered by insulation 120. Electrode 110 is situated in tissue culture well 130, with conductive liquid medium 132, cells 20 134, and nucleic acid 136. (While cells are pictured in this figure, tissue could also be used). When a voltage is first applied to electrode 110, (FIG. 1A), an electric field 140 is generated around the un-insulated portion of electrode 110. If the electric field in the medium is sufficiently high, generated Joule heat leads to rapid vaporization of liquid medium 132 in the areas adjacent to electrode 110, resulting in generation of a vapor bubble 150 (FIG. 1B). As 25 soon as vapor bubble 150 is formed, it disconnects the surface of electrode 110 from conductive medium 132, so that the electric current stops flowing, and the electric field on the target cells is 5 WO 2007/022403 PCT/US2006/032249 terminated. To overcome this difficulty, the vapor in the bubble can be ionized to form ionized vapor 160, which restores the electrical conductivity, as shown in FIG. 1C. Ionized vapor 160, also known as plasma, forms a kind of virtual electrode with electric field 170. During this process, the formation of the vapor bubble, and its subsequent collapse, causes a propagating 5 shock wave through the medium, exposing the cells or tissue to mechanical stress 180. The combination of the shock wave and the electric field leads to permeabilization of cells 132, such that nucleic acid 136 may enter cells 132 (FIG. 1D). Highlighting the role of the plasma mediated electric discharge, the inventors have named this technique electron avalanche mediated transfection, or, for simplicity, the avalanche method. 10 The process described in FIG. 1 works when the electrode produces a relatively uniform electric field. Alternatively, electrodes with a very uneven electric field may be used, so that the vapor cavity formed at the apex does not cover the whole surface of the electrode with a lower electric field. This way the electric current to the medium will not be completely disconnected. One 15 example of an electrode geometry with a non-uniform electric field is a cylindrical probe, such as a wire, with a sharp end. FIG. 2A shows an image of a wire electrode 210 producing a plasma discharge 220. As can be seen from FIG. 2A, the plasma discharge is clearly visible. It is also clearly audible. FIG. 2B shows current 230 and voltage 240 versus time when a voltage is applied to a wire probe. In this particular example, the wire probe was 50 [tm in diameter and 20 electrical pulses of up to 600 V were used to produce an electric field at the tip of the wire of about 30 kV/cm. However, these parameters may be varied. FIG. 2B shows that when a voltage is applied to such a probe, the initial 20 Rs of the waveform exhibits reduction of the current due to beginning of vaporization. This is followed by stabilization of conductivity following ionization of the vapor cavity. The ionized vapor cavity serves as a transient electrode, which 25 can greatly exceed the size of the probe, as shown in FIG. 2A. As a result, the distribution of the 6 WO 2007/022403 PCT/US2006/032249 electric field becomes much more uniform than the one generated initially on the small wire electrode, thus leading to more uniform electroporation of the target cells or tissue. FIG. 2C shows, for different diameters of electrodes, the field strength (kV/mm) along the 5 length of electrode 230 covered by insulator 240. The electrode diameter indicated by the solid line 250 is 10 p Tm, the dotted line 260 is 25 pm, and the dashed line 270 is 50 pnm. In this particular experiment, 600 V was applied to the electrode. FIG. 2C shows that for a cylindrical electrode with a sharp tip, there is a rapid decrease in electric field as one moves farther away from the tip of the electrode. Thus, the strength of the electric field at the apex of the electrode 10 can be varied by changing the electrode diameter. Various types of probes may be used according to the present invention. FIG. 3 shows a version of a probe in which active electrodes 310 are plated on a substrate 320. FIG. 3A shows a top view and FIG. 3B shows a side view of the probe. In this probe, substrate 320 is surrounded by 15 return electrode 330. The pattern of active electrodes 310 on substrate 320 forms the necessary proportion between electric field 340 and mechanical stress wave 350 due to plasma discharge 352. The probe in FIG. 3 has a singularity of the electric field 340 at the edges 312 of active electrodes 310. Singularities serve as ignition points for plasma discharge 352 and generation of mechanical stress wave 350. In FIG. 1, plasma occupies the whole volume of the vapor cavity. 20 In contrast, in FIG. 3, the electric field at the edges of the thin electrode is much higher than in front of its flat part so vaporization and ionization will occur (or start) primarily there. This implementation is simple and inexpensive, but it does not provide the flexibility to control mechanical and electric pulse parameters separately. 25 Another probe implementation, which allows separate control of mechanical stress wave 450 and electric field 440, is shown in FIG. 4. (FIG. 4A is a top view, FIG. 4B is a side view). In this 7 WO 2007/022403 PCT/US2006/032249 implementation, two types of active electrodes, 410 and 412, are patterned on substrate 420, with return electrode 430 surrounding substrate 420. Electrodes 412 may be driven to generate an electric field 440, while electrodes 410 may be driven to generate plasma 452 and mechanical stress wave 450. (Plasma 454 also generates an accompanying electric field, not shown). 5 Separate control of the amplitude of stress wave and electric field might be desirable for optimization of permnneabilization. Generating them on the same electrode will make these values mutually dependent, while generation on two separate electrodes may provide independent control of these phenomena. 10 FIG. 5 shows an example of a transfection device suitable for molecular delivery of nucleic acid to adherent cells or tissue according to the present invention. In this arrangement, cells 510 are growing on an adherent surface 520 placed in a nonporous substrate 530, such as a tissue culture plate. Adherent surface 520 may be, for example, a tissue culture insert made of porous material such as polycarbonate. Cells could also be grown directly on nonporous substrate 530. A 15 gelatinous matrix and/or feeder layer may also be present (not shown). A probe 540 with pillar electrodes 542, return electrode 544, and connection 546 to a voltage source (not shown) is brought into a solution 550 containing nucleic acid 560. Pillar electrodes 542 are positioned a finite distance from cells 510, e.g. about 1 mm. This finite distance is preferably in the range of about 0.5 mm to about 2 cm. In the embodiment shown, the return electrode 544 extends beyond 20 pillar electrodes 542 a distance equal to this finite distance such that the finite distance is defined when the return electrode 544 is touching adherent surface 520. However, this distance could be defined by any substance. In addition, pillar electrodes 542 are preferably about 0.5 mm to about 2 cm apart. 25 FIG. 6 shows an example of a transfection device suitable for molecular delivery of nucleic acid to cells or tissue in solution according to the present invention. In this arrangement, cells or 8 WO 2007/022403 PCT/US2006/032249 tissue 610 are suspended in solution 620 with nucleic acids 630 in cuvette 640. Cuvette 640 contains return electrode 642, pillar electrodes 644, and connection 646 to a voltage source (not shown). In this design, pillar electrodes 644 are preferably between about 0.5 mm and about 2 cm apart to provide adequate coverage of the solution volume. In this arrangement, the pillar 5 electrodes could be simultaneously or alternately active. Regardless of probe design, to produce a strong stress wave, the electric field on the electrode surface should be sufficient for rapid vaporization of the liquid medium. In addition, to maintain connectivity, the electric field should be high enough to induce ionization of the vapor. In this 10 way, both a mechanical stress wave and an electric field can be synchronized, with maximal intensity at the surface of the electrode. In addition to these concerns, the plasma discharge must be controlled in order to maximize transfection efficiency and minimize cell death. Several parameters may be varied to meet the above requirements, such as electric field strength, 15 applied voltage, pulse duration, number of pulses, frequency, etc. The actual values of these parameters will depend on the specific electrode geometry. In general, however, applied voltages are preferably in the range of about 1 V to about 10 kV, more preferably between about 100 V and about 1 kV. Applied voltage preferably results in an electric field between about 1 to about 100 kV/cm, more preferably about 10 to about 50 kV/cm, and most preferably about 30 20 kV/cm. Pulse duration is preferably in the range of about 1 ns to about 100 ms, more preferably between about 100 ns and about 1 ms. Either monophasic or biphasic pulses are suitable for the purposes of the present invention. However, biphasic pulses are preferred as they lead to less gas formation, nerve and muscle response, and electrode erosion. Any number of pulses may be used according to the present invention. The number of pulses is preferably between about 1 and 25 100, more preferably between about 1 and 50. When multiple pulses are used, the frequency of 9 WO 2007/022403 PCT/US2006/032249 pulses should be in the range of about 0.1 Hz to about 1 kHz. Preferably, the frequency is less than about 1 kHz to prevent heat accumulation. Cells and Tissues 5 Any cell or tissue may be suitable for practicing the invention. Examples include primary cells, primary tissues, and cell lines. Preferred cells include conjunctival fibroblasts, epithelial cells and scleral cells. Preferred tissues include conjunctival tissue and scleral tissue. Preferred cell lines include fibroblast cell lines and muscle cell lines. The cells and tissue are preferably autologous or allogeneic. 10 In one embodiment, the method of the present invention involves obtaining tissue from a subject having or at risk of developing an undesirable eye condition. The condition can range from a minor or nuisance condition, such as dry eye, to a more serious disease with possible vision loss, such as age-related macular degeneration. Under the care of a skilled medical provider, tissue 15 from the patent is harvested in an invasive, minimally invasive, or non-invasive procedure, the degree of invasiveness dictated, in part, by the tissue to be harvested. Candidate tissues are preferably those capable of transfection and production of a protein, and that are capable of survival in the transplanted environment. 20 In one aspect of this embodiment, tissue is harvested from the eye and it is contemplated that any tissue in the eye may be harvested in any feasible manner. For example, conjunctival fibroblasts can be excised from the eye by, for example, anesthetizing the conjunctiva with a topical agent such as propraracaine, cleansing and preparing the area with betadine or another cidal agent, and then taking a snip biopsy with a pair of toothed forceps and Wescott scissors. Subconjunctival 25 anesthesia may be preferred by some surgeons or patients. The excised conjunctiva or other tissue is removed and then transfected either in the operating room or in an adjacent area then 10 WO 2007/022403 PCT/US2006/032249 reimplanted in the appropriate location in the same session. Alternatively the tissue can be maintained under sterile conditions, taken to a sterile facility where transfection and subsequent subculture and testing can be performed, and reimplantation of the tissue performed one to three weeks later. A similar procedure can be performed on the sclera, except it may be preferred to 5 use subconjunctival rather than topical anesthesia. In some instances alternative tissue substrates such as iris pigment epithelium may be substituted for conjunctiva or sclera. Although a tissue sample of any size or dimension can be removed, typically a tissue sample of approximately one cubic millimeter of tissue or less is obtained. After removal of the tissue, the site can sutured or treated as needed. 10 In an alternative embodiment, the tissue is harvested from a donor, rather than the patient. In this case, donor tissue would be isolated and transfected as described above for autologous transplantation. It may be transplanted after transfection in the same session, or, alternatively the tissue can be maintained under sterile conditions, taken to a sterile facility where transfection and 15 subsequent subculture and testing can be performed, and reimplantation of the tissue performed one to three weeks later. In this case, donor tissue may be tested to determine suitability of transplantation, for example for viral or other pathogens or immunocompatibility with recipient. Nucleic Acids 20 Harvested cells or tissues, cell lines made from these cells or tissues, or standard cell lines are genetically modified according to the present invention with a nucleic acid as described above. The nucleic acid may encode, for example, a therapeutic protein or an RNAi cassette, such as a shRNA. Alternatively, the nucleic acid may be used to repair or replace an endogenous gene, for example DNA used for homologous recombination, or an oligonucleotide used for gene repair. 25 Modifications include, for example, modifying expression levels of the gene and/or replacing a mutant gene with a wild-type copy of the gene. The nucleic acid may be DNA or RNA, but is 11 WO 2007/022403 PCT/US2006/032249 preferably DNA. Also preferably, the nucleic acid is a DNA construct, in particular a cDNA or synthetic DNA, and can be further modified to improve transcription and/or translation in the host cell, or to reduce or minimize gene silencing. The nucleic acid construct may comprise, operably linked, a promoter region, a nucleotide, and optionally, a termination signal. 5 Preferably, this construct is part of a plasmid. Preferably, the cells or tissue are stably transfected so that the transplanted cells or tissue may act, for example, as a bio-factory to produce a therapeutic protein for a long period of time. Multiple nucleic acid sequences can be introduced into the cells or tissue, including multiple 10 copies of the same nucleic acid sequence and/or multiple copies of differing nucleic acid sequences encoding for different therapeutic or marker proteins. In one embodiment, each nucleic acid sequence is present on a separate polynucleotide construct, plasmid, or vector. In another embodiment, both nucleic acid sequences are present on one polynucleotide construct, plasmid, or vector, with each sequence under the control of a separate promoter. Alternatively, 15 and in yet another embodiment, both nucleic acid sequences are present on one polynucleotide construct, plasmid, or vector, with the polynucleotide structured so that it is bicistronic and where both nucleic acid sequences are under the control of a single promoter. These various embodiments are further described below. 20 With respect to the embodiments where two differing nucleic acid sequences are present on one polynucleotide construct, plasmid, or vector, each sequence can be under the control of a separate promoter or can be under the control of a single promoter. In addition to a first nucleic acid sequence encoding for a selected therapeutic protein, in this embodiment, a second nucleic acid sequence encoding, for example, a second therapeutic protein or a marker is included in the 25 construct. Expression of this gene may be constitutive; in the case of a selectable marker this may be useful for selecting successfully transfected cells or for selecting cells or transfected 12 WO 2007/022403 PCT/US2006/032249 populations of cells that are producing particularly high levels or optimal therapeutic levels of the protein. It will also be appreciated that a selectable marker may be used to provide a means for enriching for transfected cells or positively selecting for those cells which have been transfected, before reintroducing the cells into the patient, as will be described below. 5. Markers may include selectable drug resistance genes, metabolic enzyme genes, fluorescent proteins, bioluminescent proteins, or any other markers known in the art. Exemplary fluorescent proteins include, but are not limited to: green fluorescent protein, cyan fluorescent protein, yellow fluorescent protein, DsRed fluorescent protein, AsRed fluorescent protein, HcRed 10 fluorescent protein, and maxFP-green protein. When a marker gene is included in the vector construct, it will be appreciated that the marker can be used to quantify the amount of fluorescence after transfection and/or before transplantation and/or after transplantation. Quantitative determination of fluorescence can be undertaken after transfection but before transplanting the tissue using, for example, fluorescence microscopy, flow cytometry, or 15 fluorescence-activated cell sorting (FACS) analysis, in order to quantify the expression of fluorescence markers ex vivo. After transplanting the tissue, in vivo monitoring of the extent of fluorescence, as a measure of production of the therapeutic protein, can be done by examining the patient with a fluorescent ophthalmoscope or a surgical microscope equipped for fluorescence imaging, and can be documented with a CCD camera. It will be appreciated that 20 the marker gene can be used to indicate levels of transgene expression and can be monitored by a non-invasive or a minimally invasive procedure. If marker gene expression decreases, another tissue implant can be inserted into the patient to increase the level of therapeutic protein. By using a marker gene, diminished expression of the therapeutic protein can be recognized early, rather than waiting until decreased levels of the therapeutic gene lead to disease progression. 25 13 WO 2007/022403 PCT/US2006/032249 It will be evident that for many gene therapy applications, selection for expression of a marker gene may not be possible or necessary. Also, it is possible that for in vivo applications, vectors without any internal promoters may be preferable. Single transcription unit vectors, which may be bi-cistronic or poly-cistronic, coding for one or two or more therapeutic genes, may be 5 designed. Where two or more genes are present and under transcriptional control of a single promoter, there may be an internal ribosome entry site (IRES), e.g. from picornaviral RNA, to allow both genes to be separately translated from a single transcript. Retroviruses incorporating IRES 10 sequences are known in the art, for example in U.S. Patent No. 5,665,567. Briefly, in bicistronic or multicistronic vectors, the individual reading frames of the gene segments encoding the proteins lie on the transcription unit (expression unit). Expression of each cistron is effected using a single promoter, in conjunction with a specific nucleic acid sequence, typically untranslated regions of individual picorna viruses, e.g. poliovirus or encephalomyocarditis virus, 15 or a cellular protein, e.g. BiP. In the picorna viruses, a short segment of the 5' untranslated region, the so-called IRES (internal ribosomal entry site) functions as an initiator for translation of reading frames. By way of a specific example, and with reference to FIG. 7, the cells or tissue can be transfected 20 with a plasmid having one promoter that drives the expression of a first therapeutic protein, such as pigment epithelium-derived factor (PEDF), and of a selectable marker, such as a fluorescent protein like enhanced green fluorescent protein (eGFP) under control of a cytomegalovirus (CMV) promoter. The CMV promoter is positioned at the 5' end of the construct. Downstream of the 3' end of the CMV promoter is the PEDF nucleotide sequence that encodes for PEDF 25 protein. In the 3' direction of PEDF is an IRES site, which is designed to allow translation of 14 WO 2007/022403 PCT/US2006/032249 multiple genes on an mRNA transcript. Following the IRES site in the 3' direction is the eGFP coding sequence. The IRES will allow translation of eGFP as well as translation of PEDF. The promoter region of the construct can be chosen from among all promoter regions that are 5 functional in mammalian cells, in particular human cells. The promoter can be a strong or weak promoter, a constitutive or a regulated/inducible promoter, a ubiquitous or selective promoter. The promoter can be of different origin such as cellular, viral, artificial, and the like. Particular types of promoters are house-keeping promoters, i.e., promoters from cellular genes expressed in mammalian tissues or cells, or viral promoters (CMV, LTR, SV40, etc.). Furthermore, the 10 promoter region can be modified artificially to include enhancer element(s), inducibility element(s) and the like. The promoter, secretion and termination region sequences can be selected and adapted by the skilled artisan based on the polypeptide, the pathology, the vector used, etc. In this regard, the nucleic acid construct can be inserted into various kinds of vectors such as plasmids, episomes, artificial chromosomes and the like. 15 The nucleic acid construct can optionally include a secretion signal, positioned between the promoter and coding regions, which allows, or facilitates, the secretion of the polypeptide outside of the cells. The secretion signal may be homologous with respect to the polypeptide (i.e., from the same gene) or heterologous thereto (i.e., from any other gene encoding a secreted 20 polypeptide, in particular a mammalian gene, or artificial). Examples of secretion signals include the signal peptide of vascular endothelial growth factor (VEGF), pre pro nerve growth sequence (NGS), and the like. Various approaches may be used to achieve long-term expression of the nucleic acid in the cells 25 or tissue. One approach involves a circular vector carrying a recombination site and the polynucleotide sequence encoding for the therapeutic protein, shRNA, etc., and the transfection 15 WO 2007/022403 PCT/US2006/032249 is accompanied by introduction of a recombinase that facilitates recombination between the vector's recombination site and a second recombination site in the genome of the cell being transfected. Constructs carrying a recomnbination site, such as a phiC31 attB site, are described, for example, in U.S. Patent No. 6,632,672, which is incorporated by reference herein. It will be 5 appreciated, however, that other means for long-term gene expression are contemplated, such as the other members of the serine recombinase family, transposases (e.g., "Sleeping Beauty"), DNA mini-circles, plasmids optimized for minimal gene silencing, or the_use of a stable extrachromasomal vector such as EBV. When using a phiC31 attB recombination site, the nucleic acid constructs are comprised of the phiC31 integrase system (described in U.S. patents 10 6,632,672 and 6,808,925, which are incorporated by reference herein) to achieve site-specific integration into a target genome of interest. Bacteriophage phi-C31 integtrase recognizes pseudo-recombination sites present in eukaryotic cells. For genetic manipulation of a eukaryotic cell, phiC31 integrase and a vector carrying a 15 phiC31 wild-type recombination site are placed into the cell. The wild-type recombination sequence aligns itself with a sequence in the eukaryotic cell genome and the phiC31 integrase facilitates a recombination that results in integration of a heterologous gene into the eukaryotic genome. It is contemplated that any attB site, any attP site, or any pseudo att site is present on any nucleotide sequence used to introduce genetic material into the genome of the harvested or 20 cultured cells. Accordingly, in one embodiment, the method of integrating a polynucleotide sequence into a genome of a cell comprises introducing into the cell (i) a circular targeting construct, comprising a first recombination site and a polynucleotide sequence of interest, and (ii) a phiC31 integrase, 25 native or modified, wherein the genome of the cell comprises a second recombination site (i.e. a 16 WO 2007/022403 PCT/US2006/032249 pseudo att site) native to the human genome. Recombination between the first and second recombination sites is facilitated by the site-specific integrase. The therapeutic gene and the attB sequence are preferably introduced into the target cell as 5 circular plasmid DNA. The integrase may be introduced into the target cell (i) as DNA encoding the integrase on a second plasmid, (ii) mRNA encoding the integrase, or (iii) in polypeptide form. Once phiC31 is introduced into the cell, the cell is maintained under conditions that allow recombination between the first and second recombination sites and the recombination is mediated by the phiC31 integrase. The result of the recombination is site-specific integration of 10 the polynucleotide sequence of interest in the genome of the cell. By way of a specific example, and with reference again to FIG. 7, a plasmid is constructed having a cytomegalovirus (CMV) promoter that drives the expression of a therapeutic protein, pigment epithelium-derived factor (PEDF), and as a marker, enhanced green fluorescent protein 15 (eGFP). In the 3' direction of the PEDF nucleotide sequence is an IRES site, followed in the 3' direction by the eGFP coding sequence. The IRES allows translation of eGFP as well as translation of PEDF. The plasmnid, which also includes an attB nucleic acid sequence, is detailed in Example 1 and the plasmid sequence is identified herein as SEQ ID NO: 1. 20 Transfection of a wide variety of genes encoding for therapeutic proteins is contemplated, and preferred candidate genes include genes that encode for diffusible proteins that act extracellularly to have a therapeutic effect. In a preferred embodiment, a nucleic acid sequence coding for a protein with anti-angiogenic activity or with neurotrophic activity is transfected into human cells. Exemplary proteins include, but are not limited to, pigment epithelium-derived 25 factor (PEDF), truncated soluble VEGF receptor sFlt-1, truncated soluble VEGF receptor sFlk-1, VEGFR-1, VEGFR-2, angiostatin, endostatin, tissue inhibitor of metalloprotease 3 (TIMP-3), 17 WO 2007/022403 PCT/US2006/032249 ExTek, ciliary neurotrophic factor (CNTF), brain-derived neurotrophic factor (BDNF), bone morphogenetic protein 4 (BMP4), alpha fibroblast growth factor (aFGF), beta fibroblast growth factor (bFGF), and any protein having activity on or within the compliment factor H pathway. Preferred biologically active polypeptides exhibit neurotrophic and/or anti-angiogenic activity. 5 The most preferred biologically active polypeptides are autogenic and thus do not invoke an immune response in the subject or are known in the art not to invoke an immune response. In a preferred embodiment, human cells are genetically modified to contain a recombinant nucleic acid construct that directs the cells to produce the therapeutic protein encoded by the 10 recombinant nucleic acid. The cells can be immediately transplanted into the subject or can be cultured in vitro for a period of time. In a preferred embodiment, mammalian cells modified with a vector containing at least one nucleic acid sequence coding for a therapeutic protein and another nucleic acid sequence coding for a marker gene are prepared for transplantation. When the cells are cultured in vitro prior to transplantation, a selection step can be performed in order 15 to isolate the cells that effectively contain the recombinant nucleic acid construct and express the polypeptide. The selection step will depend in part on the marker gene and can involve measuring fluorescence, screening for antibiotic resistance, or the like. Cells expressing the marker gene are selected for transplantation. In general, when the cells are cultured for a period of time after transfection, the treatment method is performed on a subject over more than one 20 visit to the medical provider. In a first visit, the tissue is harvested. The tissue cells are transfected and cultured in vitro, during which time the level of expression can be monitored and stably-transfected cells from the tissue selected, by, for example, quantifying expression of a marker or of the desired protein by methods noted above for measuring marker expression, for transplantation. The subject returns to the medical provider for a second visit during which the 25 transfected tissue is transplanted. 18 WO 2007/022403 PCT/US2006/032249 Alternatively, tissue can be obtained, transfected, and transplanted during a single patient visit to a medical provider. In this scenario, the level of expression of a marker or the desired therapeutic protein can be monitored in vivo, by methods mentioned above, such as ophthalmoscope or a surgical microscope. 5 In a preferred embodiment, one or more nucleotide sequences coding for a therapeutic protein and one nucleotide sequence coding for a marker gene are present in the same polynucleotide vector construct. The marker gene is coupled to the therapeutic gene by an IRES sequence. Quantification of the degree of fluorescence emitted from a cell or group of clonal cells would 10 correlate with the amount of expression of the therapeutic protein, enabling selection of stably transfected cells or monitoring of protein expression after transplantation. Transplantation The transfected tissue or cells can be transplanted into the subject in any of a number of different 15 implantation sites in or near the eye by a provider of medical care. FIG. 8 is a diagram showing an eye 800 in cross-sectional view, and indicating some of the preferred sites for placing genetically modified cells or tissue into the patient. Identified anatomical features are retina 830, sclera 840, optic nerve 850, cornea 860, pupil 870 and iris 880. Sites in eye 800 preferred for implanting the transfected cells or tissue include the vitreous humor 810, near the pars plana 820, 20 near the posterior retina 832, or sub-sclerally 842. Other sites for implanting tissue, which are not specifically indicated in FIG. 8, include the choroid, retinal pigment epithelium (RPE), and near the macula epi-retinally, sub-retinally, or intra-retinally. In a preferred embodiment, the transfected cells or tissue are implanted into the subject in the 25 absence of an encapsulating member, such as a polymer capsule or a so-called "cage". Especially in the case where the method described herein employs autologous tissue or cells, encapsulation 19 WO 2007/022403 PCT/US2006/032249 of the tissue or cells within a cage is not necessary for immunosuppression. However, encapsulation could be used to enhance graft survival and/or to reduce possible splintering of cells away from the graft to other sites in the eye. A number of cage designs have been proposed for ophthalmologic use for various purposes, as described in U.S. Patent Nos. 6,500,449 and 5 6,663,894. The cage would be able to house the tissue or cell transplant and would have pores large enough for proteins to diffuse out, but small enough so that cells could not enter or leave. The cage may contain a matrix or other materials to support cell survival and cell anchoring to prevent cell migration to other sites. 10 EXAMPLES The following examples are illustrative in nature and are in no way intended to be limiting. Example 1: Construction of a plasmid for transfection The plasmid shown in FIG. 7 contains the sequence SEQ ID NO: 1 . SEQ ID NO: 1 includes a 15 cytomegalovirus (CMV) promoter (1-589 bp), a nucleotide sequence encoding for pigment epithelium-derived factor (PEDF; 590-2131 bp), an internal ribosome entry site (IRES) coding sequence (b2151-2735 bp), and a nucleotide sequence encoding for enhanced green fluorescent protein (eGFP; bp 2739-3455), an sv40 polyA sequence (3612-3662 bp), a phi C31 attB site (3952-4245 bp), a bacterial kan promoter (4541-4576 bp), SV40 origin and promoter enhancer 20 (4653-4955 bp), neo for G418 selection (5004-5798 bp), and an pUC origin (6383-7026 bp). To make this plasmid, begin with vector pIRES-EGFP, commercially available from Clontech. Cut the vector with the restriction enzyme BsaI (New England Biolabs) to linearize the vector, make blunt ends (e.g., using DNA Polymerase I, Large (Klenow) Fragment, New England 25 Biolabs), and treat with a phosphatase to remove the phosphate groups (e.g., using calf intestinal phosphatase, New England Biolabs). Ligate this vector to the fragment containing attB when 20 WO 2007/022403 PCT/US2006/032249 pTA-attB+ is cleaved with EcoRI and then its ends blunted, to form the plasmid plRES-EGFP attB. In the second cloning step, use PCR amplification with primers designed to amplify the PEDF 5 gene from human cDNA. Cleave pIRES-EGFP-attB with the restriction enzyme Sinal, which linearizes the plasmid upstream of the IRES sequence and use a phosphatase to remove the phosphate groups. Ligate the PCR-amplified fragment into the vector to form the plasmid pPEDF-IRES-GFP-attB, shown in FIG. 7. 10 Example 2: Transfection of conjunctival tissue with luciferase gene A study was conducted in support of the method described herein, where a luciferase marker gene was transfected into conjunctiva tissue. Conjunctival tissue was explanted from adult New Zealand White rabbits and placed in tissue culture dishes. All samples were placed in 1 mL phosphate buffered saline solution with 100 micrograms of plasmid DNA encoding the 15 luciferase gene under a CMV promoter. All samples were cultured in Dulbecco's Modified Eagle Medium (DMEM) plus 10% serum and antibiotic/antimicotic for 24 hours after transfection. Samples were then treated with luciferin substrate (150 micrograms luciferin per ml medium) and imaged using the IVIS-200 system (Xenogen Corp.). 20 The conjunctival tissue, which contained conjunctival fibroblasts, was transfected using electron avalanche mediated transfection with a luciferase marker gene. A control sample of tissue was contacted with the luciferase gene in the absence of electron-avalanche mediated transfection. Twenty-four hours after transfection, bioluminescence was measured. As shown in FIG. 9, the tissue transfected with electron-avalanche mediated transfection emitted 2.2 x 105 photons/sec, 25 two orders of magnitude higher than the cells transfected in the absence of the electron 21 WO 2007/022403 PCT/US2006/032249 avalanche mediated transfection (4.6 x 103 photons/sec). Background emission was measured at 3.7 x 10' photons/sec. Example 3: Comparison of electron avalanche versus traditional electroporation in DNA 5 transfer Because electroporation protocols vary for different tissues, experiments were first conducted to determine the optimal protocol for transfecting CAM from a developing chicken egg using traditional electroporation. CAM is a live, readily available, and inexpensive tissue. Its epithelial layer is unifonnr and has high resistance, making it a good model for epithelial cell layers, such 10 as retinal pigment epithelium. In this model system, 100 [tg of pNBL2 plasmid DNA encoding the luciferase gene was pipetted onto the CAM, and pulses were applied. Specifically, a 250-ps, 150-V phase, followed by a 5-ms, 5-V phase in the same polarity was applied. Optimal results were achieved with 50 cycles applied at 1 Hz. The tissue was then cultured and assayed for luciferase bioluminescence. Luciferase expression using this method was about 104 photons/s. 15 For electron-avalanche transfection, a 50-Rm wire microelectrode 1 mm in length was used to apply a series of symmetric biphasic pulses, with each phase 250 us in duration and 600 V in amplitude. The microelectrode was scanned over a 4-mm 2 area, and approximately 50 pulses were applied. As shown in FIG. 10, the resultant luciferase expression was about 109 photons/s, 20 10,000-fold higher than levels seen with conventional electroporation. As one of ordinary skill in the art will appreciate, various changes, substitutions, and alterations could be made or otherwise implemented without departing from the principles of the present invention. Accordingly, the scope of the invention should be determined by the following claims 25 and their legal equivalents. 22
Claims (25)
1. A method of treating an ocular disease in a subject, comprising: a. introducing a nucleic acid into cells or a tissue using electron avalanche-mediated 5 transfection; and b. transplanting said cells or said tissue comprising said nucleic acid into an ocular region of said subject.
2. The method as set forth in claim 1, wherein said avalanche-mediated transfection comprises inducing a vapor bubble and a plasma discharge between an electrode and 10 a conductive fluid surrounding said cells or said tissue.
3. The method as set forth in claim 1, wherein said cells are primary cells or cell lines.
4. The method as set forth in claim 3, wherein said cells are autologous or allogeneic.
5. The method as set forth in claim 1, wherein said cells are conjunctival fibroblasts, 15 scleral cells, or epithelial cells.
6. The method as set forth in claim 1, wherein said tissue is conjunctival tissue or scleral tissue.
7. The method as set forth in claim 1, further comprising culturing said cells or said tissue prior to said transplanting. 20
8. The method as set forth in claim 1, wherein said transplanting further comprises placing said cells or said tissue in an implantable device.
9. The method as set forth in claim 8, wherein said implantable device comprises a cage or a capsule.
10. The method as set forth in claim 1, wherein said nucleic acid is DNA. 25
11. The method as set forth in claim 1, wherein said nucleic acid encodes a therapeutic protein, an oligonucleotide, an RNAi cassette. 23 WO 2007/022403 PCT/US2006/032249
12. The method as set forth in claim 11, wherein said RNAi cassette comprises a short-hairpin RNA.
13. The method as set forth in claim 11, wherein said therapeutic protein has at least one of anti-angiogenic activity or neurotrophic activity. 5
14. The method as set forth in claim 11, wherein said therapeutic protein has activity on or with the complement factor H pathway.
15. The method as set forth in claim 1, wherein said nucleic acid is part of a plasmid.
16. The method as set forth in claim 15, wherein said plasmid further comprises at least one of a phiC31 attB site or a marker gene. 10
17. The method as set forth in claim 16, wherein said marker gene encodes a fluorescent protein.
18. The method as set forth in claim 16, further comprising providing a source of phiC31 integrase.
19. The method as set forth in claim 1, wherein said nucleic acid is an oligonucleotide 15 introduced for gene repair.
20. The method set forth in claim 1, wherein said nucleic acid is DNA suitable for homologous recombination.
21. The method as set forth in claim 1, wherein said ocular region comprises at least one of the choroid, vitreous humor, retinal pigment epithelium, near the macula, and 20 behind the sclera.
22. The method as set forth in claim 21, wherein said ocular region is epiretinal to said macula, subretinal to said macula, or intra-retinal to said macula.
23. The method as set forth in claim 21, wherein said ocular region comprises a region of the vitreous humor that is near the pars plana. 24 WO 2007/022403 PCT/US2006/032249
24. The method as set forth in claim 1, wherein said disease is selected from the group consisting of age-related macular degeneration, choroidal neovascularization, retinal degeneration, glaucoma, diabetic retinopathy, and retinal dystrophies.
25. The method as set forth in claim 1, wherein said subject is a mammal. 525 25
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US70848605P | 2005-08-15 | 2005-08-15 | |
US60/708,486 | 2005-08-15 | ||
US36098406A | 2006-02-22 | 2006-02-22 | |
US11/360,984 | 2006-02-22 | ||
PCT/US2006/032249 WO2007022403A2 (en) | 2005-08-15 | 2006-08-15 | Ocular gene therapy using avalanche-mediated transfection |
Publications (1)
Publication Number | Publication Date |
---|---|
AU2006279395A1 true AU2006279395A1 (en) | 2007-02-22 |
Family
ID=37758427
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AU2006279395A Abandoned AU2006279395A1 (en) | 2005-08-15 | 2006-08-15 | Ocular gene therapy using avalanche-mediated transfection |
Country Status (5)
Country | Link |
---|---|
EP (1) | EP1924698A4 (en) |
JP (1) | JP2009507780A (en) |
AU (1) | AU2006279395A1 (en) |
CA (1) | CA2620294A1 (en) |
WO (1) | WO2007022403A2 (en) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9226790B2 (en) | 2011-02-01 | 2016-01-05 | M.O.E. Medical Devices Llc | Plasma-assisted skin treatment |
US9351790B2 (en) | 2011-09-17 | 2016-05-31 | M.O.E. Medical Devices Llc | Electrode geometries and method for applying electric field treatment to parts of the body |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8101169B2 (en) * | 2005-02-23 | 2012-01-24 | The Board Of Trustees Of The Leland Stanford Junior University | Ocular gene therapy using avalanche-mediated transfection |
WO2009062149A1 (en) * | 2007-11-08 | 2009-05-14 | Creighton University | Methods for maintaining inner ear neurons |
WO2012086702A1 (en) * | 2010-12-24 | 2012-06-28 | タカラバイオ株式会社 | Method for gene introduction |
EP2670477B1 (en) * | 2011-02-01 | 2015-11-25 | Moe Medical Devices LLC | Plasma-assisted skin treatment |
EP3199201A1 (en) * | 2011-09-17 | 2017-08-02 | Moe Medical Devices LLC | Systems for electric field and/or plasma-assisted onychomycosis treatment |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6267954B1 (en) * | 1999-11-24 | 2001-07-31 | Universite De Paris V Rene-Descartes | Intraocular transplantation of encapsulated cells |
US20050148530A1 (en) * | 2002-02-20 | 2005-07-07 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of vascular endothelial growth factor and vascular endothelial growth factor receptor gene expression using short interfering nucleic acid (siNA) |
-
2006
- 2006-08-15 EP EP06801803A patent/EP1924698A4/en not_active Withdrawn
- 2006-08-15 AU AU2006279395A patent/AU2006279395A1/en not_active Abandoned
- 2006-08-15 WO PCT/US2006/032249 patent/WO2007022403A2/en active Application Filing
- 2006-08-15 CA CA002620294A patent/CA2620294A1/en not_active Abandoned
- 2006-08-15 JP JP2008527156A patent/JP2009507780A/en active Pending
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9226790B2 (en) | 2011-02-01 | 2016-01-05 | M.O.E. Medical Devices Llc | Plasma-assisted skin treatment |
US9351790B2 (en) | 2011-09-17 | 2016-05-31 | M.O.E. Medical Devices Llc | Electrode geometries and method for applying electric field treatment to parts of the body |
Also Published As
Publication number | Publication date |
---|---|
EP1924698A4 (en) | 2010-12-15 |
CA2620294A1 (en) | 2007-02-22 |
WO2007022403A3 (en) | 2010-04-22 |
WO2007022403A2 (en) | 2007-02-22 |
EP1924698A2 (en) | 2008-05-28 |
JP2009507780A (en) | 2009-02-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US8101169B2 (en) | Ocular gene therapy using avalanche-mediated transfection | |
JP5000638B2 (en) | Improved method and apparatus for delivering a therapeutic product to a subject's eye | |
JP6220785B2 (en) | Methods and pharmaceutical compositions for the treatment of eye diseases in a subject | |
AU2006279395A1 (en) | Ocular gene therapy using avalanche-mediated transfection | |
JP7371083B2 (en) | Intraocular delivery of gene therapy expression vectors | |
Touchard et al. | The ciliary smooth muscle electrotransfer: basic principles and potential for sustained intraocular production of therapeutic proteins | |
Chen et al. | Targeted gene expression in the chicken eye by in ovo electroporation | |
Chalberg et al. | Gene transfer to rabbit retina with electron avalanche transfection | |
JP2014524302A (en) | Device for the treatment of eye diseases | |
JP6058667B2 (en) | Device for the treatment of eye diseases | |
US20070123486A1 (en) | Composition for coordinated VEGF and PDGF expression, and methods of use | |
Chalberg et al. | AVALANCHE ELECTROPORATION AND 4> C31 INTEGRASE FOR GENE TRANSFER TO RABBIT RETINA | |
JP4464098B2 (en) | Method for electroporation | |
US9315829B2 (en) | Methods for intracellular delivery of nucleic acids | |
Palanker et al. | Plasma-mediated transfection of RPE | |
McFarland et al. | Genetic Approach to Retinal Vascular Disease | |
McFarland et al. | 10 Genetic Approach to Retinal Vascular Disease 10.1 Gene Therapy for Proliferative Ocular Disease | |
Stephens | Development of gene therapy for the treatment of inherited retinal degeneration |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
MK4 | Application lapsed section 142(2)(d) - no continuation fee paid for the application |